The Continuing Plague of Extended-Spectrum β-Lactamase Producing Enterbacterales Infections An Update

被引：19
作者：
Adler, Amos [1 ,2 ]
Katz, David E. [3 ]
Marchaim, Dror [2 ,4 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Clin Microbiol Lab, 6 Weizmann St, IL-6423906 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[3] Shaare Zedek Med Ctr, Div Internal Med, 12 Shmuel Bait St, IL-9103102 Jerusalem, Israel
[4] Shamir Assaf Harofeh Med Ctr, Unit Infect Control, IL-7030000 Zerifin, Israel
来源：
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2020年 / 34卷 / 04期
关键词：
Gram-negative; MDRO; Escherichia coli; Klebsiella pneumoniae; Proteus mirabilis; BLOOD-STREAM INFECTIONS; URINARY-TRACT-INFECTIONS; IN-VITRO ACTIVITY; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; ESBL-PRODUCING KLEBSIELLA; SUSCEPTIBLE STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI INFECTION; CARE-ASSOCIATED INFECTIONS; GRAM-NEGATIVE BACTERIA; RISK-FACTORS;
D O I：
10.1016/j.idc.2020.06.003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Antimicrobial resistance is a common iatrogenic complication of modern life and medical care. One of the most demonstrative examples is the exponential increase in the incidence of extended-spectrum beta-lactamases (ESBLs) production among Enterobacteriaceae, that is, the most common human pathogens outside of the hospital setting. Infections resulting from ESBL-producing bacteria are associated with devastating outcomes, now affecting even previously healthy individuals. This poses an enormous burden and threat to public health. This article aims to narrate the evolving epidemiology of ESBL infections and highlights current challenges in terms of management and prevention of these common infections.
引用
收藏
页码：677 / +
页数：33
相关论文
共 250 条
[31]   High Diversity of Extended-Spectrum β-Lactamases in Escherichia coli Isolates from Italian Broiler Flocks [J].
Bortolaia, Valeria ;
Guardabassi, Luca ;
Trevisani, Marcello ;
Bisgaard, Magne ;
Venturi, Luciano ;
Bojesen, Anders Miki .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (04) :1623-1626
[32]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[33]   Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST) [J].
Bouchillon, Sam K. ;
Iredell, Jonathan R. ;
Barkham, Timothy ;
Lee, Kyungwon ;
Dowzicky, Michael J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (02) :130-136
[34]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951
[35]  
Bratzler Dale W, 2013, Am J Health Syst Pharm, V70, P195, DOI [10.1089/sur.2013.9999, 10.2146/ajhp120568]
[36]  
BRUNBUISSON C, 1987, LANCET, V2, P302
[37]   Extended-spectrum β-lactamases in North America, 1987-2006 [J].
Bush, K. .
CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :134-143
[38]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[39]   Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria [J].
Bush, Karen ;
Fisher, Jed F. .
ANNUAL REVIEW OF MICROBIOLOGY, VOL 65, 2011, 65 :455-478
[40]   European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis [J].
Cagnacci, Simone ;
Gualco, Laura ;
Debbia, Eugenio ;
Schito, Gian Carlo ;
Marchese, Anna .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (08) :2605-2612
12345678910